

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

Claims 1-8. (Cancelled).

Claim 9. (New) A method for treating bone lesions in a patient suffering from multiple myeloma and bone lesions by both inhibiting proliferation of myeloma cells and suppressing bone resorption, comprising administering to said patient a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof, and a pharmaceutically acceptable carrier or diluent.

Claim 10. (New) The method of treating bone lesions according to Claim 9, wherein 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally in a dose of 1 to 20 mg per day.

Claim 11. (New) The method of treating bone lesions according to Claim 9, wherein 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof is administered orally in a dose of 3 to 10 mg per day.

Claim 12. (New) A method of both inhibiting myeloma cell proliferation and suppressing bone resorption, comprising administering orally 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or a salt thereof in a dose of 1 to 20 mg per day to a patient suffering from multiple myeloma and bone lesions.